Transgenic TIEG non-human animals

Details Transgenic TIEG non-human animals Transgenic TIEG non-human animals

2007-12-04

2007-12-04

Woitach, Joseph (Department: 1633)

Multicellular living organisms and unmodified parts thereof and

Nonhuman animal

Transgenic nonhuman animal

C800S013000, C800S014000

Reexamination Certificate

active

10944454

ABSTRACT:
Materials and methods related to a transgenic non-human animal (e.g., a transgenic non-human mammal) whose genome comprises a disrupted TIEG allele are provided. Methods for making such transgenic non-human animals, and using them to identify and characterize agents that affect conditions related to TIEG activity, such as cardiac hypertrophy and bone formation also are provided. In addition, materials and methods related to the treatment of hypertrophic cardiomyopathy are provided.

REFERENCES:
patent: 3687808 (1972-08-01), Merigan, Jr. et al.
patent: 4415732 (1983-11-01), Caruthers et al.
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4469863 (1984-09-01), Ts'o et al.
patent: 4959317 (1990-09-01), Sauer
patent: 5214136 (1993-05-01), Lin et al.
patent: 5218105 (1993-06-01), Cook et al.
patent: 5235033 (1993-08-01), Summerton et al.
patent: 5464764 (1995-11-01), Capecchi et al.
patent: 5596086 (1997-01-01), Matteucci et al.
patent: 5750666 (1998-05-01), Caruthers et al.
patent: 5889136 (1999-03-01), Scaringe et al.
Fautsch., et al., Characterization of the mouse TGFbeta-inducible early gene (TIEG): conservation of exon and transcriptional regulatory sequences with evidence of additional transcripts. Mamm Genome. Oct. 9, 1998(10):838-42.
Fautsch et al., GFβ-Inducible Early Gene (TIEG) Also Codes for Early Growth Response α (EGRα): Evidence of Multiple Transcripts from Alternate Promoter. Genomics 51, 1998, pp. 408-416.
Subramaniam et al., ,TIEG1 Null Mouse-Derived Osteoblasts Are Defective in Mineralization and in Support of Osteoclast Differentiation in VitroMolecular and Cellular Biology, Feb. 2005, p. 1191-1199, vol. 25, No. 3.
Reinholz et al., 2004. Differential gene expression of TGFβ inducible early gene (TIEG), Smad 7, Smad 2, and Bard 1 in normal and malignant breast tissue. Breast Cancer Res. Treatment 166:75-88.
Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci. May 1996;19(5):177-81.
Capecchi MR. Altering the genome by homologous recombination.Science. Jun. 16, 1989;244(4910):1288-92. Review.
Holschneider DP, Shih JC. Genotype to phenotype: challenges and opportunities. Int J Dev Neurosci. Oct. 2000;18(6):615-8.
Leonard WJ, Shores EW, Love PE. Role of the common cytokine receptor gamma chain in cytokine signaling and lymphoid development. Immunol Rev. Dec. 1995;148:97-114.
Griffiths I, et al., Current concepts of PLP and its role in the nervous system. Microsc Res Tech. Jun 1, 1998;41(5):344-58.
Crabbe JC, Wahlsten D, Dudek BC.Genetics of mouse behavior: interactions with laboratory environment. Jun. 4, 1999;284(5420):1670-2.
Rajamannan NM et al., J Cell Biochem. Feb. 1, 2007;100(2):315-25.TGFbeta inducible early gene-1 (TIEG1) and cardiac hypertrophy: Discovery and characterization of a novel signaling pathway.
Capecchi, “Targeted Gene Replacement. Researchers can now create mice bearing any chosen mutations in any known gene. The technology is revolutionizing the study of mammalian biology,”Scientific American, 1994, 270(3):34-41.
Mansour et al., “Mice homozygous for a targeted disruption of the proto-oncogeneint-2have developmental defects in the tail and inner ear,”Development, 1993, 117:13-28.
GenBank Accession No. AF049879 dated Nov. 17, 1998.
GenBank Accession No. AF049880 dated Nov. 17, 1998.
GenBank Accession No. AF050110 dated Sep. 3, 1998.
GenBank Accession No. U21847 dated Jan. 16, 1996.
Arad et al., “Phenotypic diversity in hypertrophic cardiomyopathy,”Human Molecular Genetics, 2002, 11(20):2499-2506.
Bender et al., “TIEG1 Facilitates Transforming Growth Factor-β-Mediated Apoptosis in the Oligodendroglial Cell Line OLI-neu,”J. Neuroscience Research, 2004, 75:344-352.
Blok et al., “Characterization of an Early Growth Response Gene, Which Encodes a Zinc Finger Transcription Factor, Potentially Involved in Cell Cycle Regulation,”Molecular Endocrinology, 1995, 9:1610-1620.
Burel et al., “Dichotomy of AML1-ETO Functions: Growth Arrest versus Block of Differentiation,”Molecular and Cellular Biology, 2001, 21(16):5577-5590.
Chalaux et al., “A zinc-finger transcription factor induced by TGF-β promotes apoptotic cell death in epithelial Mv1Lu cells,”FEBS Letters, 1999, 457:478-482.
Cibelli et al., “Cloned Transgenic Calves Produced from Nonquiescent Fetal Fibroblasts,”Science, 1998, 280:1256-1258.
Dennler et al., “Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene,”The EMBO J., 1998, 17(11):3091-3100.
Geisterfer-Lowrance et al., “A Mouse Model of Familial Hypertrophic Cardiomyopathy,”Science, 1996, 272:731-734.
Gingery et al., “Phosphatidylinositol 3-Kinase Coordinately Activates the MEK/ERK and AKT/NFκB Pathways to Maintain Osteoclast Survival,”J. Cell. Biochem., 2003, 89:165-179.
Guatelli et al., “Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication,”Proc. Natl. Acad. Sci. USA, 1990, 87:1874-1878.
Heaney and Melmed, “Pituitary tumour transforming gene: a novel factor in pituitary tumour formation,”Baillière's Clinical Endocrinology and Metabolism, 1999, 13(3):367-380.
Hyrup and Nielssen, “Peptide Nucleic acids (PNA): Synthesis, Properties and Potential Applications,”Bioorgan. Med. Chem., 1996, 4(1):5-23.
James et al., “Transgenic Modeling of a Cardiac Troponin I Mutation Linked to Familiar Hypertrophic Cardiomyopathy,”Circ. Res., 2000, 87:805-811.
Johnsen et al., “Modulation of Transforming Growth Factor β (TGFβ)/Smad Transcriptional Responses through Targeted Degradation of TGFβ-inducible Early Gene-1 by Human Seen in Absentia Homologue,”J. Biol. Chem., 2002, 277(34):30754-30759.
Johnsen et al., “Transcriptional Regulation of Smad2 is Required for Enhancement of TGFβ/Smad Signaling by TGFβ Inducible Early Gene,”J. Cell. Biochem., 2002, 87:233-241.
Johnsen et al., “TGFβ Inducible early gene enhances TGFβ/Smad-dependent transcriptional responses,”Oncogene, 2002, 21:5783-5790.
Kakar, “Molecular cloning, genomic organization, and identification of the promoter for the human pituitary tumor transforming gene (PTTG),”Gene, 1999, 240:317-324.
Koli and Arteaga, “Complex Role of Tumor Cell Transforming Growth Factor (TGF)-βs on Breast Carcinoma Progression,”J. Mammary Gland Biology and Neoplasia, 1996, 1(4):373-380.
Kook et al., “Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop,”J. Clin Invest., 2003, 112:863-871.
Lewis, “PCR's Competitors Are Alive and Well and Moving Rapidly Towards Commercialization,”Genetic Engineering News, 1992, 12(9):1-3.
Lin et al., “Control of Mouse Cardiac Morphogenesis and Myogenesis by Transcription Factor MEF2C,”Science, 1997, 276:1404-1407.
Marian et al., “A transgenic rabbit model for human hypertrophic cardiomyopathy,”J. Clin. Invest., 1999, 104:1683-1692.
Maron et al., “Hypertrophic Cardiomyopathy. Interrelations of Clinical Manifestations, Pathophysiology, and Therapy (First of Two Parts),”New Engl. J. Med., 1987, 316(13):780-789.
Maron et al., “Hypertrophic Cardiomyopathy. Interrelations of Clinical Manifestations, Pathophysiology, and Therapy (Second of Two Parts),”New Engl. J. Med., 1987, 316(14):844-852.
Miyamoto et al., “A Dominant-negative Mutant of Androgen Receptor Coregulator ARA54 Inhibits Androgen Receptor-mediated Prostate Cancer Growth,”J. Biol. Chem., 2002, 277(7):4609-4617.
Molkentin et al., “A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy,”Cell, 1998, 93:215-228.
Moustakas et al., “Mechanisms of TGF-

Affiliated with

Also associated with

Rating

Transgenic TIEG non-human animals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transgenic TIEG non-human animals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic TIEG non-human animals will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3846835